Personalis expands Tempus deal to include colorectal cancer testing

6 hours ago 2
Using AI technology helps with genetic code prediction research.

Suriphon Singha/iStock via Getty Images

  • Personalis (NASDAQ:PSNL) said it has expanded its partnership with Tempus AI (NASDAQ:TEM) to include colorectal cancer in their exclusive commercialization agreement.
  • This collaboration will focus on launching the NeXT Personal test, which is designed to detect cancer recurrence in breast, lung, and

Recommended For You

More Trending News

Read Entire Article